''On standalone basis
Quarter ended September 2024 compared with Quarter ended September 2023.
Net sales (including other operating income) of RPG Life Sciences has increased 12.13% to Rs 172.21 crore. Operating profit margin has jumped from 24.28% to 26.67%, leading to 23.17% rise in operating profit to Rs 45.93 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 23.42% to 12.60%. Purchase of finished goods cost rose from 8.23% to 15.94%. Employee cost decreased from 21.09% to 20.03%. Other expenses fell from 23.84% to 23.62%.
Other income up 6.01% to Rs 1.94 crore. PBIDT rose 22.37% to Rs 47.87 crore. Provision for interest up 70% to Rs 0.17 crore. Loan funds remained nil. Inventories declined from Rs 100.57 crore as of 30 September 2023 to Rs 99.16 crore as of 30 September 2024. Sundry debt...
Pleaselogin & subscribe to view the full report.
More Reports
|
|